SELLAS Life Sciences Group Inc buy Heureka
Start price
27.02.20
/
50%
€2.39
Target price
09.03.20
€3.00
Performance (%)
-23.10%
End price
09.03.20
€1.84
Summary
This prediction ended on 09.03.20 with a price of €1.84. The prediction for SELLAS Life Sciences Group Inc disappointed with a performance of -23.10%. Heureka has 50% into this predictionSELLAS Life Sciences is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapies for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, is a cancer immunotherapy being developed for the treatment of acute myeloid leukemia (AML) and ovarian cancer. SELLAS Life Sciences is listed on the NASDAQ stock exchange under the symbol RXII.
AI-generated
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| SELLAS Life Sciences Group Inc | -13.391% | -13.391% | 550.980% | 569.355% |
| iShares Core DAX® | 0.855% | 0.389% | 2.533% | 52.003% |
| iShares Nasdaq 100 | -0.989% | -4.400% | 25.154% | 77.536% |
| iShares Nikkei 225® | -1.781% | -11.216% | 44.398% | 64.676% |
| iShares S&P 500 | 0.057% | 0.778% | 20.953% | 63.009% |